Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

OnKure Therapeutics, Inc. - Class A Common Stock (NQ:OKUR)

2.265 -0.085 (-3.62%)
Delayed Quote Updated: 2:49 PM EDT, Oct 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about OnKure Therapeutics, Inc. - Class A Common Stock

News headline image
OnKure Therapeutics Spotlights Allosteric PI3Kα Drugs as 2027 IND Targets Near ↗
OnKure Therapeutics (NASDAQ:OKUR) used a scientific webcast to outline its strategy for developing mutant-selective PI3Kα inhibitors, emphasizing allosteric inhibition as a potential way to improve... 
Via MarketBeat
What's going on in today's pre-market session ↗
Via Chartmill
News headline image
OnKure Therapeutics Inc-A (NASDAQ:OKUR) Reports Q2 2025 Earnings Beat with Narrower-Than-Expected Loss ↗
OnKure Therapeutics (OKUR) reported Q2 2025 EPS of -$1.14, beating estimates, with no revenue. Stock rose 1.5% after hours. Clinical progress on OKI-219 cancer drug remains on track for Q4 2025 data. 
Via Chartmill
Topics Earnings
News headline image
Gilead Sciences To Rally Around 11%? Here Are 10 Top Analyst Forecasts For Tuesday ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Recently Listed Cancer Firm OnKure's Innovative Approach to Breast Cancer Treatment Sparks Analyst Enthusiasm ↗
OnKure Therapeutics has garnered attention following its merger with Reneo Pharmaceuticals and a $65 million private placement. Oppenheimer initiated coverage with an Outperform rating, highlighting... 
Via Benzinga
News headline image
This Builders FirstSource Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗
 
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.